HM95573 + cetuximab

HM95573 (belvarafenib) is an investigational, orally available small-molecule inhibitor of RAF serine/threonine protein kinases (including ARAF, BRAF, and CRAF), designed to disrupt the RAF/MEK/ERK signaling pathway that drives tumor proliferation in cancers carrying BRAF, KRAS, or NRAS mutations. Cetuximab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), inhibiting EGFR-mediated signaling and thereby impeding cancer cell growth and survival. The combination of HM95573 and cetuximab is being evaluated primarily for solid tumors harboring RAS or RAF pathway mutations, leveraging the dual blockade of RAF and EGFR signaling pathways to overcome resistance mechanisms observed in cancer therapy[1][3][5].

Other names

belvarafenib + cetuximab